Gene transcription of receptors for growth hormone-releasing peptide and somatostatin in human pituitary adenomas
- PMID: 9709982
- DOI: 10.1210/jcem.83.8.5046
Gene transcription of receptors for growth hormone-releasing peptide and somatostatin in human pituitary adenomas
Abstract
Growth hormone (GH)-releasing peptides (GHRP) or secretagogs (GHS) constitute a family of synthetic compounds with potent and specific GH releasing activity. The receptor (GHS-R) has recently been cloned even though the endogenous ligand remains to be identified. GHRPs act both at the hypothalamic and the pituitary level through mechanisms involving amplification of GH-releasing hormone activity and functional somatostatin antagonism. In the present study we examined the co-expression of messenger RNA (mRNA) for GHS-R and all 5 somatostatin receptor subtypes (sstr 1-5) in 28 human pituitary tumors by RT-PCR. GHS-R transcription was detected in 11 out of 12 somatotroph adenomas and in 2 out of 2 prolactinomas, whereas GHS-R expression was detected in only 2 out of 14 clinically nonfunctioning adenomas (NFPA), and no expression was seen in the only ACTH secreting adenoma. Almost all tumors expressed sstr 2 mRNA (n = 24), whereas only 1 tumor expressed sstr 4 mRNA. The expression of sstr 3 mRNA was inversely associated with GHS-R expression (P < 0.001), which could be attributed to a high prevalence of sstr 3 expression in NFPA. This study suggests that GHS-R expression is predominantly observed in somatotroph adenomas and much less so in NFPA. Moreover, the presence of a distinct pattern of somatostatin receptor subtype co-expression is suggested, which may provide a molecular basis for the complex interaction between GHRPs and somatostatin.
Similar articles
-
Expression of the growth hormone secretagogue receptor in pituitary adenomas and other neuroendocrine tumors.J Clin Endocrinol Metab. 1998 Oct;83(10):3624-30. doi: 10.1210/jcem.83.10.5210. J Clin Endocrinol Metab. 1998. PMID: 9768675
-
Expression of somatostatin receptors on human pituitary adenomas in vivo and ex vivo.J Endocrinol Invest. 2001 Jun;24(6):430-7. doi: 10.1007/BF03351043. J Endocrinol Invest. 2001. PMID: 11434667
-
Somatostatin receptor subtype gene expression in pituitary adenomas.J Clin Endocrinol Metab. 1995 Apr;80(4):1386-92. doi: 10.1210/jcem.80.4.7714115. J Clin Endocrinol Metab. 1995. PMID: 7714115
-
Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects.J Endocrinol Invest. 2005;28(11 Suppl International):36-42. J Endocrinol Invest. 2005. PMID: 16625843 Review.
-
Genetic abnormalities of somatostatin receptors in pituitary tumors.Mol Cell Endocrinol. 2008 May 14;286(1-2):180-6. doi: 10.1016/j.mce.2007.08.013. Epub 2007 Aug 31. Mol Cell Endocrinol. 2008. PMID: 17913341 Review.
Cited by
-
Lipophilization of somatostatin analog RC-160 improves its bioactivity and stability.Pharm Res. 1999 Jul;16(7):1047-53. doi: 10.1023/a:1018935800052. Pharm Res. 1999. PMID: 10450929
-
Mifepristone: is there a place in the treatment of Cushing's disease?Endocrine. 2013 Aug;44(1):20-32. doi: 10.1007/s12020-012-9846-1. Epub 2012 Nov 29. Endocrine. 2013. PMID: 23192246 Review.
-
Medical management of Cushing's disease: what is the future?Pituitary. 2012 Sep;15(3):330-41. doi: 10.1007/s11102-012-0397-5. Pituitary. 2012. PMID: 22674211 Free PMC article. Review.
-
Ghrelin in neuroendocrine organs and tumours.Pituitary. 2007;10(3):213-25. doi: 10.1007/s11102-007-0023-0. Pituitary. 2007. PMID: 17530417 Review.
-
Mapping of somatostatin receptor types in GH or/and PRL producing pituitary adenomas.J Clin Pathol. 2006 Mar;59(3):274-9. doi: 10.1136/jcp.2005.026914. J Clin Pathol. 2006. PMID: 16505278 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical